Table 1 Summary of therapeutic antibodies combined with inhibition of autophagy

Rituximab

CD20

CQ

Non-Hodgkin lymphoma

[151]

Bevacizumab

VEGF

CQ

HCC

[152]

Cetuximab

EGFR

CQ

Vulvar squamous carcinoma

[147]

Overexpressed Bcl-2

Colorectal adenocarcinoma

siRNA ATG7

Lung adenocarcinoma

siRNA Beclin1

Gemtuzumab ozogamicin

CD33

PP242

Acute myeloid leukemia

[153]

AZD2014

[154]

DN30

Met

Baf

Cardiomyoblasts

[155]

DO24

Trastuzumab

HER2

CQ

Breast cancer

[148]

Milatuzumab

CD74

FTY720

Mantle cell lymphoma

[156]

Tositumomab

CD20

Overexpressed Bcl-2

B cell malignancies

[157]

siRNA Beclin1

siRNA ATG 12

CH12

EGFRvIII

siRNA ATG7

HCC

[158]

siRNA Beclin1

β2M mAb

β₂-microglobulin

Bortezomib

Multiple myeloma

[159]

PD-1 mAb

PD-1

Pemetrexed + sildenafil

Non-small cell lung cancer

[160]

CTLA4 mAb

CTLA4